CClinicalTrials.gg
CompletedNCT00865254Updated Jun 28, 2013

Prize Reinforcement for Smoking Cessation

An interventional study of Standard Treatment and Traditional Contingency Management in Nicotine Dependence, sponsored by Wayne State University. Completed at 1 site in United States. Open to participants aged 13 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-06-28.

Sponsored by Wayne State University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
13 Years and older
Sex
All
01

Study summary

Nicotine dependence is prevalent in society, cigarette smoking is associated with several known health risks, and most dependent individuals find it very difficult to stop smoking cigarettes. The present study will test the efficacy of a behavioral smoking cessation treatment, prize-based contingency management, that has not undergone rigorous study with respect to smoking, it but has demonstrated efficacy in reducing use of other substances (e.g. cocaine). If efficacious, prize-based contingency management would add to our repertoire of efficacious smoking cessation treatments.

Read the detailed description

Contingency management (CM) treatments are efficacious in reducing substance use. A relatively new approach, called prize-based CM, which uses prizes to reinforce substance abstinence, is effective in decreasing certain types of substance use, but its efficacy has not been evaluated in the treatment of cigarette smoking. One purpose of the current study is to assess the efficacy of a prize reinforcement intervention for reducing cigarette smoking. A second purpose is to test the differential efficacy of two schedules of reinforcement, using cigarette smoking as an exemplar. We will randomly assign 110 patients to one of three conditions: 1) Standard treatment; 2) Traditional prize reinforcement; or 3) Early-treatment enhanced prize reinforcement. Patients in each condition will receive counseling for their smoking based on current standard of care guidelines. All patients will participate in a one-week baseline period, followed by a four-week intervention. Throughout both phases, each patient will meet with a research assistant twice daily to provide carbon monoxide (CO) samples. Patients in the prize reinforcement conditions will earn the chance to win prizes when they provide negative CO samples (i.e., \< 6ppm). They will also earn bonus draws if they provide negative cotinine samples (i.e., \<100ng/ml) after weekends. Patients in the Traditional CM condition will have at least a 50% chance of winning a prize for each negative sample with escalating chances for successive negative samples. Patients in the Enhanced condition will have the opportunity to earn the same overall number of draws and magnitude of reinforcement, but the schedule of reinforcement will differ. For the first week of the CM phase, these patients will have a 100% chance of winning prizes, but in the latter 3 weeks, overall probability of reinforcement will be decreased to 34%. Patients will also undergo 2- and 6-month follow-up assessments. Primary outcome measures will be longest duration of continuous abstinence and mean number of days of abstinence. We predict that the prize reinforcement will reduce cigarette smoking to a greater extent than standard treatment. We also predict that the Enhanced CM condition will lead to greater reductions in cigarette smoking relative to the Traditional CM condition, and that these changes may result in longer sustained abstinence from smoking throughout the study period.

02

Conditions studied

  • Nicotine Dependence

Browse trials for

Keywords

  • Nicotine Dependence
  • Smoking
  • Smoking Cessation
  • Contingency Management
03

In context

Tobacco Use Disorder

968 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

This study's enrollment of 84 is close to the median of 90 across 851 interventional studies indexed under Tobacco Use Disorder.

Browse Tobacco Use Disorder studies →

Lead sponsor

Wayne State University is the lead sponsor of 226 studies on the registry; 35 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. A current Fagerstrom scale score of 6 or greater;
  2. Age 13 years old or older (Under age 18, parental consent is required);
  3. Able to read and understand English.

Exclusion criteria

Exclusion Criteria:

  1. Have current severe, uncontrolled psychiatric disorders (i.e., acute suicidality or psychosis);
  2. Have current substance dependence, other than nicotine or caffeine dependence;
  3. Are in recovery for pathological gambling; or
  4. Are already participating in other behavioral or medication smoking cessation programs.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
84 participants (actual)

Study arms

  • Experimental
    Traditional Contingency Management

    Standard treatment plus prize based contingency management.

    Behavioral: Traditional Contingency Management

  • Experimental
    Early Enhanced Contingency Management

    Prize based contingency management with enhanced magnitude early in treatment and reduced magnitude later in treatment.

    Behavioral: Early Enhanced Contingency Management

  • Active comparator
    Standard Treatment

    Counseling and monitoring of smoking cessation.

    Behavioral: Standard Treatment

Interventions

  • BehavioralStandard Treatment

    Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.

  • BehavioralTraditional Contingency Management

    Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.

  • BehavioralEarly Enhanced Contingency Management

    Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.

06

What researchers measure

Primary outcomes

  1. Expired Carbon Monoxide

    Time frame: Baseline and treatment phases, 2-mont and 6-month follow up.

Secondary outcomes

  1. Self-reported smoking.

    Time frame: Baseline, throughout treatment, 2-month and 6-month follow up.

  2. Cotinine levels.

    Time frame: Baseline, throughout treatment, 2-month and 6-month follow up.

07

Study locations

1 site
  • Wayne State University, Jefferson Avenue Research Clinic
    Detroit, Michigan 48207, United States
08

References and documents

Publications

  • Reid HH, Ledgerwood DM. Depressive symptoms affect changes in nicotine withdrawal and smoking urges throughout smoking cessation treatment: Preliminary results. Addict Res Theory. 2016;24(1):48-53. doi: 10.3109/16066359.2015.1060967. Epub 2015 Jun 26. PubMed 27547173 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 28, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00865254
Lead sponsor
Wayne State University
Collaborators
National Institute on Drug Abuse (NIDA)
Responsible party
David Ledgerwood (Assistant Professor, Wayne State University) — Principal investigator
First posted
Mar 19, 2009
Start date
Aug 2007
Primary completion
Jul 2011
Completion
Jul 2011
Last update
Jun 28, 2013

Study contacts

David M Ledgerwood, Ph.D.
principal investigator · Wayne State University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion